GENEART Appoints Daniel Seibert as New Chief Financial Officer

Tuesday, 02. June 2009 10:00
- Daniel Seibert completes GENEART's management board
- Financial expert with over ten years experience in executive
positions
- New board member possesses broad competences in managing fast
growing companies

Regensburg, June 2, 2009 - GENEART AG's supervisory board appointed
Daniel Seibert as member of the management board with immediate
effect. He assumes the position of the Chief Financial Officer (CFO)
and is responsible for the areas of finances, controlling,
procurement and human resources.

Daniel Seibert (40) is a business graduate ("Diplom-Kaufmann") and
possesses many years of experience managing quickly growing companies
in dynamic industries. During his most recent engagement, he acted on
behalf of financial investors in the renewable energies sector as
Chief Financial Officer of Renergys Group AG, Zurich. Previously, he
was responsible for business development, restructuring and
controlling of the Scout24 Holding GmbH, as commercial managing
director. Moreover, Daniel Seibert possesses extensive experience in
the areas of capital market oriented evaluation of businesses,
mergers and acquisitions as well as the integration of companies,
from his position as Head of Investment Analysis & Controlling with
T-Online International AG. He started his career at American Express
in 1996.

Prof. Dr. Ralf Wagner, CEO of GENEART AG: "I am pleased that with the
appointment of Daniel Seibert as CFO, we attracted a highly qualified
expert for the position, who perfectly complements our management
team. In the long term, we are now superbly positioned to benefit
disproportionally high from our market's growth potential."

The management team around Prof. Dr. Ralf Wagner (Chief Executive
Officer and Chief Scientific Officer) now consists of Dr. Marcus
Graf, the company's co-founder, responsible for production (Chief
Operating Officer), Bernd Merkl, as Chief Business Officer in charge
of Sales, Marketing and Business Development, and the newly appointed
Chief Financial Officer Daniel Seibert.

For further inquiries, please contact:

Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.

About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the synthetic biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001:2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. GENEART AG in
Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto
(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190
people. GENEART is listed on the German Stock Exchange.


This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.

View document
Related Links: GENEART AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.